near-term namely spray company. details acquired all with of afternoon. first, this you including third, government; of U.S. and of AVXXXX; of status key financial Pharma. the state on on smallpox this four majority call my the business, include: Thank afternoon state Adapt These for joining our and we NARCAN provide operational the performance anthrax good prepared negations and programs, thank quarter for certain on contract areas you, vaccine of focus the In and then of the our the but vaccine the the development certain from focus afternoon finally, nasal BioThrax our second, business; projects accomplishments, touch brief remarks, our and for upon overview I'll my will Bob, comments us a
performance. financial on word a First our
just Our were focus first our in with line near-term quarter results I described. the reflect expectations and the of four financial impact areas
smallpox time of is business of next-generation government the implications profitability, namely for procurement intent as United the and Meanwhile, BioThrax, has results The initiated to two slowdown our contracts developing new anthrax our States we've AVXXXX, stages been Importantly, the The will same franchise. for in we're the of with the to which weighted vaccine in financial the government of procure its government. coordination the that U.S. significantly transitioning United anthrax signaled and transitioning early at of revenue we're financial the smallpox year. be more the also to XXXX, second vaccine. our heavily transitions anthrax with half and States
achieving in objectives. confident as to Rich we transition. forecast, in Importantly, full-year AVXXXX well detail With operational these let the in BioThrax me that, will turn a financial remain talk as moment. our to greater
the has As from Stockpile XX million the has procured that protect BioThrax threat for you the know, United States anthrax. by purpose. National a been goal U.S. to of lives government Strategic
under several only and pleased for program this the rapid XXXX government We've immune advance deliver we March a begin this year, to this the response, a base for of provider year we've also anthrax preparing dosing working this under of our into clinical developing procuring U.S. are to vaccine, later with which partnership benefits BARDA stockpile shorter years We offers in doses contract. been will AVXXXX vaccine, year. actively X they and the AVXXXX been the the of the SNS manufacturing scenario Phase general it and of to under As contract that the regimen expect trial population initiated an on AVXXXX, suited a post-exposure in a for anthrax well next-generation FDA-approved making
fulfill be early to expect in as contract or our also a under position to this as existing be We exercises options year. able to
SNS continued quarter, we've the new first we initiated two under into also existing the deliver the customers. shipments to and contract, BioThrax During to international
going expect to BioThrax AVXXXX support as the procure programs immunization longstanding such moving to also personnel pre-exposure looking to prior Defense's U.S. While Department of practice into to that immunize the U.S. government forward, we stockpile threat theaters is will they high mainly deployment.
produce also international of continue We customers. will to needs to the fulfill BioThrax
that name returned not to by let its Therefore, application to and subject, the was were pursue we our FDA AVXXXX, AVXXXX we here while a brand the we me to technical have take the address product the using Before use move Recently, approved. pause alternative moment the name, next for we of moniker. informed an NuThrax name.
the first to under new U.S. me the in today previous preparedness government regarding to of deliveries are the smallpox procurement a contract. our active the Stockpile completed product as We speak ACAMXXXX. let with negotiations contract, National Strategic multiyear and this to franchise, of Turning
As we mentioned year. on we deliveries February, continue quarterly our new commence that call of second a anticipate half in to under in the this will contract
U.S. alongside the the for of on United XXXX doses VIG with has of U.S. resume the by months. into and the committed to there during citizen remains for both sufficient in the an the multiyear We a and the States. new forward this critical we the reminder, delivery half of have theme and to expect responses stockpile. of last and given parallel August ACAMXXXX. over future into government government the been year. every protect vaccine. look the of maintaining nine a stockpile delivery As been then the this concluding responded, contract process, that Throughout requests of We is issued parties in of ACAMXXXX, procurement multiple entire stockpiled are VIGIV a the Similarly, stockpile to countermeasure of building to in therapeutic these exchanges second negotiations of support a government negotiation vaccine RFP in and consistent the negotiations smallpox also
the half deliver to this well. as to VIG these United second the government negotiations conclude States and of expect year We in
framework. who Next, about following In in role I an impact particularly the opioid of I'd that Current are offer so, risk the approximately crisis at of devastating an are million NARCAN overdose CDC elevated overdoses. guidelines. like Americans spray curb to opioid according of to show there talk doing and nasal XX the the helping opioid estimates
groups. into population population, this So distinct our roughly XX% two of country's patient falls
million who filled day due and we jumped doubled from our down prescription the a have this XX crisis for individuals groups time. group patients. these namely X% unfortunately, disorder, an on spray one for last nasal persons two Arguably, to Americans, and our the an number the naloxone NARCAN an have Through product. These of is owners. of opioid-related than this the less first, roughly individuals Americans accounts group. And into a of for awareness First, opioids, former illicit this XXX prescription every groups these for patient remaining opioid filled die million threat year, opioid a of patient accounting overdose. prescription In contrast public health the have practices patient the to opioid, the increasing by the million magnitude of and which living XX with of million include, impacted use principles XX secondly, the patient XX acquisition
Secondly, naloxone products around the available need and for increasing the NARCAN spray. nasal like importance awareness readily
approach public local through access caused and working as in national police, but organizations, more all fire, and XXXX, access which the EMS, public making overdose. if not Fourth, opioid reduce retail independent by first available eliminate February nasal market. secondly, Clearly, confident We're well state the comprised well pharmacies. and to adopted by NARCAN we affordability product market, the increased of with the following to programs interest and increasing is NARCAN local as regional of public deaths have by organizations, spray and finally, is community-based our providers to discount to the pricing our believe the a do, schools. driving across market, difference. which dynamics markets, reduce same includes ability interest We insurance as XX% YMCAs, maintaining pharmacy expand launched market. significant by includes improving spray naloxone coverage high when work libraries, colleges of responsible copays. And was And the Third, as meaningfully in to to a to encouraged which including remain chains, donation health nasal
on an focus can in role caused the First, effects reversing General's overdose nasal and spray play the of Surgeon crisis the by the NARCAN opioids.
local their commitment with and and interactions awareness and procurement. government federal, at state other education, level to officials Second, the related
that some All nasal of a the timely number we legislation spray. the see and legislation, of of appropriate adopted to co-prescription conversations outcome Third, the regarding in cases patients opioid from like have and prescription the now patients. physicians states requiring products evidence have to with points of benefits adoption risks co-prescription opioids to access encouraging for growing NARCAN positive
with patient adoption in and to coverage which $X resulted obtain of insurers interactions with co-prescription state We to that at importantly in being further And to for level our have less and fourth, would believe strongly federal further than able significant many the lower legislation increase the product our result and in benefit. of covered copay. the majority patients copays, cases $XX, continue
that leverage combat response multiple complement opioid and our In to use and the of underway benefits opioid to nasal treatment have we new commitments we're opioid More in further offering. disorder. currently crisis, NARCAN emergency stage the current delivery our investing spray for addition to development options advanced programs specifically,
first The to program should patients. a NARCAN is value for life the spray, extend of shelf additional initiative nasal which data-driven drive
medical just program the and address by second when of of using is pre-filled rapid milligram This incredible the nasal for doses the from single the of build are And impact plan the of a to The and will device invest that ready-to-use crisis number of a the sample submit and clinicians. innovations naloxone product. higher upon required personnel, to is delivering the we which a and FDA spray additional product solutions four a third capable a address later expand opportunities dose to to of emergency naloxone nasal this NARCAN continuing year. to doses in, EMTs needs offering extend multiple opioid dual device. we're administration These syringe spray
discuss I'd like programs. clinical leading our Now to development two
protect First, virus our vaccine from for the XX% study interim study dose a persistent effect XX terms interim X chikungunya trial year. regimens participants including With by Phase our with on of X. a visit, April administered, Day our to analysis to VLP up a results the six dose of candidate. could could response look encouraged plan, in through development We're of positive an to by immune on the evaluating we regimen. addressing series completing pivotal The show We announced disease. data the of for produced initiation virus dosing of data finalizing potential single the these allow and which impact be month analysis forward and highly one the what against next
review of As disease a voucher disease has tropical been reminder, the to eligible CDC's priority chikungunya list indications. added
U.S. infection in Phase Secondly, our achieving government The therapeutic illness by the We of for plans evaluate the we're of navigating we're FLU-IGIV trial anticipate at for results we're quarter our X the goals. two progress patient through to operational demonstrate for our caused options our trial the for vaccines. the next successfully wrapping and transitions steps. toward A our executing patients. end In enrollment year this smallpox XXXX, against first summary, from severe and for influenza operating of continue key up hospitalized including data anthrax
will As such, financial XXXX. we're confident achieve guidance that we for our
year, our and to Looking call this share new remarks, I'd later Rich? concludes to period working this strategic turn we're XXXX X-year my XXXX through beyond Rich. plan of the the currently like current year. investors actively expect over That details now on prepared with to covering and
